Posted by Michael Wonder on 14 Sep 2022
NICE inks another early full stop on the appraisal of a cancer medicine
14 September 2022 - Once again, the sponsor decided not to provide an evidence submission.
NICE is unable to make a recommendation on the use of melphalan hydrochloride (Phelinun) for the treatment of patients with a haematological disease before allogeneic haematopoietic stem cell transplantation because Adienne did not provide an evidence submission.
